Impact of the cyclin-dependent kinase inhibitor p27(Kip1) on resistance of tumor cells to anticancer agents

Nature Medicine

Volumn 2, Issue 11, 1996, Pages 1204-1210

  St Croix, Brad ^a,b   Flørenes, Vivi Ann ^a,b   Rak, Janusz W ^a,b   Flanagan, Mike ^c   Bhattacharya, Nandita ^a,b   Slingerland, Joyce M ^a,b   Kerbel, Robert S ^a,b  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^c GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; ENZYME INHIBITOR; PROTEIN;

ANIMAL CELL; ARTICLE; CARCINOMA CELL; CELL ADHESION; CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG RESISTANCE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL ADHESION; CELL CYCLE PROTEINS; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; CYCLINS; DRUG RESISTANCE, NEOPLASM; HUMANS; MICE; MICROTUBULE-ASSOCIATED PROTEINS; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

ANIMALIA;

EID: 0001405430     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1196-1204     Document Type: Article

References (51)

1. Tannock, I. Cell kinetics and chemotherapy: A critical review. Cancer Treat. Rep. 62, 1117-1133 (1978).
2. Tannock, I.F. Principles of cell proliferation: Cell kinetics, in: Current Cancer Therapeutics, (eds. Kirkwood, J.M., Lotze, M.T. & Yasko, J.M.) 3-13 (Princeton Academic Press, Princeton, New Jersey, 1994).
3. Sutherland, R.M. Cell and environment interactions in tumor microregions: The multicell spheroid model. Science 240, 177-184 (1988).
4. Olive, P.L. & Durand, R.E. Drug and radiation resistance in spheroids: Cell contact and kinetics. Cancer Metastasis Rev. 13, 121-138 (1994).
5. Teicher, B.A. et al. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science 247, 1457-1461 (1990).
6. Kobayashi, H., Man, S., Kapitain, S.J., Teicher, B.A. & Kerbel, R.S. Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc. Natl. Acad. Sci. USA 90, 3294-3298 (1993).
7. St. Croix, B. et al. Reversal by hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells. J. Natl. Cancer Inst. 88, 1285-1296 (1996).
8. Kerbel, R.S. et al. Multicellular resistance: A new paradigm to explain aspects of acquired drug resistance of solid tumors. Cold Spring Harbor Symp. Quant. Biol. 59, 661-672 (1994).
9. Hoffman, R.M. The three-dimensional question: Can clinically relevant tumor drug resistance be measured in vitro? Cancer Metastasis Rev: 13, 169-173 (1994).
10. Morgan, D.O. Principles of CDK regulation. Nature 374, 131-134 (1995).
11. 1 cyclin-dependent kinases. Genes Dev. 9, 1149-1163 (1995).
12. Hunter, T. & Pines, J. Cyclins and cancer. II. Cyclin D and CDK inhibitors come of age. Cell 79, 573-582 (1994).
13. kip1 Chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res. 55, 1211-1214 (1995).
14. Kawamata, N. et al. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res. 55, 2266-2269 (1995).
15. Shiohara, M. et al. Absence of WAF1 mutations in a variety of human malignancies. Blood 84, 3781-3784 (1994).
16. kip1 in primary breast carcinomas. Hum. Genet. 97, 91-94 (1996).
17. Spirin, K.S. et al. p27/Kip1 mutation found in breast cancer. Cancer Res. 56, 2400-2404 (1996).
18. Slingerland, J.M. et al. A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor β-arrested epithelial cells. Mol. Cell. Biol. 14, 3683-3694 (1994).
19. Hengst, L., Dulic, V., Slingerland, J.M., Lees, E. & Reed, S.I. A cell cycle-regulated inhibitor of cyclin-dependent Kinases. Proc. Natl. Acad. Sci. USA 91, 5291-5295 (1994).
20. kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev. 8, 9-22 (1994).
21. Wagner, R.W. et al. Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines. Science 260, 1510-1513 (1993).
22. kip1 for restriction point control of the fibroblast cell cycle. Science 272, 877-880 (1996).
23. Reyniskottir, I., Polyak, K., Iavarone, A. & Massague, J. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-ß. Genes Dev. 9, 1831-1845 (1995).
24. Conte, P.F. et al. Conventional versus cytokinetic polychemotherapy with estrogenic recruitment in metastatic breast cancer: Results of a randomized cooperative trial. J. Clin. Oncol. 5, 339-347 (1987).
25. Gore, S.D. et al. Impact of in vivo administration of interleukin 3 on proliferation, differentiation, and chemosensitivity of acute myeloid leukemia. Clin. Cancer Res. 1, 295-303 (1995).
26. Karp, J.E. & Broder, S. Molecular foundations of cancer: New targets for intervention. Nature Med. 1, 309-320 (1995).
27. Fang, F., Orend, G., Watanabe, N., Hunter, T. & Ruoslahti, E. Dependence of cyclin E-Cdk2 kinase activity on cell anchorage. Science 271, 499-502 (1996).
28. Sano, Y., Hoshino, T., Bjerkvig, R. & Deen, D.F. The relative resistance of non-cycling cells in 9L multicellular spheroids to spirohydantoin mustard. Eur. J. Cancer Clin. Oncol. 19, 1451-1456 (1983).
29. Hinz, G. & Dertinger, H. Increased radioresistance of cells in cultured multicell spheroids. Radiat. Environ. Biophys. 21, 255-264 (1983).
30. Remvikos, Y. et al. Cell cycle modifications of breast cancers during neoadjuvant chemotherapy: A flow cytometry study on fine needle aspirates. Eur. J. Cancer 29A, 1843-1848 (1993).
31. Briffod, M. et al. Evaluation of breast carcinoma chemosensitivity by flow cytometric DNA analysis and computer assisted image analysis. Cytometry 13, 250-258 (1992).
32. Spyratos, F. et al. Sequential cytopunctures during preoperative chemotherapy for primary breast carcinoma. Cancer 69, 470-475 (1992).
33. Meredith, J.E., Jr., Fazeli, B. & Schwartz, M.A. The extracellular matrix as a cell survival factor. Mol. Biol. Cell 4, 953-961 (1993).
34. Frisch, S.M. & Francis, H. Disruption of epithelial cell-matrix interactions induces apoptosis. J. Cell Biol. 124, 619-626 (1994).
35. Bates, R.C., Buret, A., van Helden, D.F., Horton, M.A. & Burns, G.F. Apoptosis induced by inhibition of intercellular contact. J. Cell Biol. 125, 403-115 (1994).
36. Mendonca, M.S., Rodriguez, A. & Alpen, E.L. Differential repair of potentially lethal damage in exponentially growing and quiescent 9L cells. Rad. Res. 122, 38-43 (1990).
37. Little, J.B., Hahn, G.M., Frindel, E. & Tubiana, M. Repair of potentially lethal radiation damage in vitro and in vivo. Radiology 106, 689-694 (1973).
38. Dimanche-Boitrel, M.-T., Garrido, C. & Chauffert, B. Kinetic resistance to anticancer agents. Cytotechnology 12, 347-356 (1993).
39. Dimanche-Boitrel, M. et al. Confluence-dependent resistance in human colon cancer cells: Role of reduced drug accumulation and low intrinsic chemosensitivity of resting cells. Int. J. Cancer 50, 677-682 (1992).
40. Zhang, W. et al. High levels of constitutive WAF1/Cip1 protein are associated with chemoresistance in acute myelogenous leukemia. Clin. Cancer Res. 1, 1051-1057 (1995).
41. WAFI is required for survival of differentiating neuroblastoma cells. Mol. Cell. Biol. 16, 1335-1341 (1996).
42. Waldman, T., Lengauer, C., Kinzler, K.W. & Vogelstein, B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking pil. Nature 381, 713-716 (1996).
43. Wang, J. & Walsh, K. Resistance to apoptosis conferred by Cdk inhibitors during myocyte differentiation. Science 273, 359-361 (1996).
44. CIPI/WAFI normal development, but are defective in G1 checkpoint control. Cell 82, 675-684 (1995).
45. kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85, 707-720 (1996).
46. kipl. Cell 85, 721-732 (1996).
47. kipl-deficient mice. Cell 85, 733-744 (1996).
48. Tonkinson, J.L. & Stein, C.A. Antisense oligodeoxynucleotides as clinical therapeutic agents. Cancer Invest. 14(1), 54-65 (1996).
49. Hietanen, P. et al. Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer. Br. J. Cancer 71, 1029-1032 (1995).
50. O'Reilly, S.M., Camplejohn, R.S., Rubens, R.D. & Richards, M.A. DNA flow cytometry and response to preoperative chemotherapy for primary breast cancer. Eur. J. Cancer 213, 681-683 (1992).
51. Remvikos, Y. et al. Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. J. Natl. Cancer Inst. 81, 1383-1387 (1989).